Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
NCT03406299Phase 2Completed
- Sponsor
- National Health Research Institutes
- Start
- Apr 2018
- Primary completion
- Dec 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur, folinic acid and oxaliplatin in biliary tract cancer (BTC) (2 arms), sponsored by National Health Research Institutes. Primary endpoint: 6-month progression-free survival rate at 26 weeks. Started Apr 2018; status: completed.
02
Drugs
tegafurfolinic acidoxaliplatin
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03406299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406299.